Case Reports  |   May 2004
Local Anesthetic Infusion Pump Systems Adverse Events Reported to the Food and Drug Administration
Author Affiliations & Notes
  • S. Lori Brown, Ph.D., M.P.H.
  • Audrey E. Morrison, R.N.
  • * Senior Research Scientist Officer, † Nurse Consultant.
Article Information
Case Reports
Case Reports   |   May 2004
Local Anesthetic Infusion Pump Systems Adverse Events Reported to the Food and Drug Administration
Anesthesiology 5 2004, Vol.100, 1305-1307. doi:
Anesthesiology 5 2004, Vol.100, 1305-1307. doi:
THE purpose of this report is to characterize adverse event reports on continuous direct local anesthetic infusion into surgical wounds using infusion pump systems devised for this purpose. These pump systems typically consist of disposable, nonelectrical pumps or electromechanical pumps that deliver a continuous infusion at controlled rates for a specified duration of time. Postoperative pain may be managed by continuous direct infusion of anesthetic into a surgical wound. This technique is reportedly used in a variety of surgeries, e.g.  , inguinal hernia repair, 1 upper abdominal surgery, 2 laparoscopic nephrectomy, 3 cholecystectomy, 4 knee arthroplasty, 5 and shoulder 6 and gynecologic operative laparoscopy. 7 
Infusion pump systems for anesthetic wound perfusion are regulated by the U.S. Food and Drug Administration (FDA) as medical devices. The FDA monitors the performance of regulated medical devices via  a passive surveillance system.
Adverse events during direct local anesthetic infusion into surgical wounds, with an infusion pump system, have been reported to the FDA. These reports involve adverse events reported for surgeries performed at a variety of surgical sites, including orthopedic, gastrointestinal, podiatric, and others. Complications encountered with these infusion pump systems include tissue necrosis, surgical wound infection, and cellulitis. Following are examples of cases reported to the FDA and a summary of 40 injuries that occurred using direct local anesthetic infusion pump systems. These reports may represent sentinel events, i.e.  , an early warning that is representative of a problem that is widespread, or alternatively, these may be isolated incidents.
Adverse Event Reports
The following are unedited reports from the Medical Device Reporting database.
Report 1
This report describes four patients. Bupivacaine and adrenaline were infused after total knee procedures. Two patients experienced full thickness sloughs that required plastic surgical intervention and a second procedure with a gastric flap. Two additional patients experienced partial thickness sloughs in the same area, which required split thickness grafts and prolonged nursing and rehabilitation.
Report 2
The pump was attached at the end of surgery for bunionectomy to a healthy 26-yr-old woman. The catheter was placed under the skin and attached to the infusion device (plain Marcaine [AstraZeneca Pharmaceuticals LP, Waltham, MA] was used). This device automatically delivers 2 ml/h continually until the pump is empty. The continuous infusion of this fluid over time caused swelling, pain, and blistering due to cell death. There was ischemic necrosis of the blister with a full-thickness loss of tissue (slough) down to the bone with a question of osteomyelitis. Wound culture was positive for a staphylococcal species. This patient required hospitalization and was sent for wound débridement and intravenous antibiotics. She may require skin grafting.
Report 3
The surgeon placed the pump during a gastrectomy with one regular catheter and one soaker catheter in a 77-yr-old man. A serious infection developed that seemed to originate at the catheter point of entry. The device was in place for approximately 4 days. A severe infection and dehiscence resulting in evisceration developed in the patient. This patient required intervention for a life-threatening adverse event and had to undergo repeated surgery.
Table 1summarizes characteristics of 40 patients and adverse events from 34 reports to the FDA. These reports described a variety of infusion pump system models manufactured by three companies. Information on patient sex and age was usually not provided. Most surgeries were orthopedic (45.0%), typically total knee. The second most common procedure was for podiatric surgeries (20.0%), including bunionectomies, plantar fasciotomy, and others. The most commonly reported adverse event (42.5%) was tissue necrosis. The drug(s) infused were not reported in most cases (60%), but in the 16 reports that did specify, 9 were bupivacaine and adrenaline and 7 were bupivacaine only. In these 16 cases, necrosis was no more likely when both bupivacaine and adrenaline were reported than when bupivacaine alone was reported (exact test, P  = 0.20). There were also numerous reports for wound infections and systemic infection.
Table 1. Adverse Event Reports to the FDA for Disposable Continuous Infusion Pumps for Direct Anesthetic Infusion into Surgical Wounds
Image not available
Table 1. Adverse Event Reports to the FDA for Disposable Continuous Infusion Pumps for Direct Anesthetic Infusion into Surgical Wounds
The FDA received 34 reports describing 40 patients with adverse events that occurred during the use of pump systems for direct anesthetic infusion into a surgical wound. The most commonly reported complication was tissue necrosis, an adverse event almost never seen after normal procedures. The consequences of these adverse events were typically severe and required intervention and additional medical and surgical treatment. There were also numerous cases of wound infection reported, but these data do not permit us to assess the incidence of this adverse event, so it is not possible to determine whether these infections were above the expected background rate.
We reviewed the literature and found only one case series, published as a letter, that described complications associated with the use of pump systems for direct anesthetic infusion. This case series describes plastic surgery consultations for three patients referred by the same orthopedic surgeon after knee arthroplasties. 8 Two patients needed wound débridements and gastrocnemius flaps, and the third patient underwent repeated débridements and skin grafting. The likely cause of wound ischemia and necrosis was thought to be the infusion of bupivacaine with epinephrine. Reportedly, there was adequate drainage of the wound and no apparent compartment compression. The authors of the letter speculate that the adverse events were related to continuous infusion of epinephrine and subsequent vasoconstriction of the area. In adverse event reports to the FDA, some reports described similar adverse events with use of anesthetic infusion alone. These reports did not explicitly state that epinephrine was not used, and it is possible that epinephrine was used and was not mentioned in the report.
Limitations in Medical Device Reports or MedWatch data should be acknowledged. Device manufacturers, user facilities, and voluntary reporters submit reports to the FDA that are entered into an adverse events database. Accuracy and completeness of reports are not verified by the FDA. The reports do not establish a causal link between a device and an injury or patient problem. Because infection or necrosis may occur after surgery in the absence of continuous anesthetic infusion, it is not possible to definitively conclude that the reported necrosis or infections after surgery was due to infusion pump use, nor is there certainty that continuous infusion of bupivacaine or bupivacaine in combination with epinephrine caused these adverse events. Nevertheless, the reports provide a potentially important signal, suggesting the need for further investigation of the relation between use of pumps for direct continuous infusion of anesthetics and other drugs into surgical wounds and tissue necrosis, serious infections, or cellulitis.
Medical providers and consumers may report adverse events to manufacturers or directly to the FDA through MedWatch.12
Oakley MJ, Smith JS, Anderson JR, Fenton-Lee D: Randomized placebo-controlled trial of local anaesthetic infusion in day-case inguinal hernia repair. Br J Surg 1998; 85:797–9
Gibbs P, Purushotham A, Auld C, Cuschieri RJ: Continuous wound perfusion with bupivacaine for postoperative wound pain. Br J Surg 1988; 75:923–4
Ashcraft EE, Baillie GM, Shafizadeh SF, McEvoy JR, Mohamed HK, Lin A, Balinga PK, Rogers J, Rajagopalan PR, Chavin KD: Further improvements in laparoscopic donor nephrectomy: Decreased pain and accelerated recovery. Clin Transplantation 2001; 15(suppl 6):59–61
Chester JF, Ravindranath K, White BD, Shanahan D, Taylor RS: Wound perfusion with bupivacaine: Objective evidence for postoperative pain relief. Ann R Coll Surg Eng 1989; 71:394–6
DeWeese FT, Akbari Z, Carline E: Pain control after knee arthroplasty. Clin Orthop Related Res 2001; 392:226–31
Savoie FH, Field LD, Jenkins RN, Mallon WJ, Phelps RA II: The pain control infusion pump for post operative pain control in shoulder surgery. Arthroscopy 2000; 16:339–42
Stringer NH, Rodino KL, Edwards M, Kumari NVA: On-Q system for managing trocar site pain after operative laparoscopy. J Am Assoc Gynecol Laparosc 2000; 7:552–5
Smoot EC, Colpitts R: Wound complications of infusion pain pump therapy (letter). Plast Reconstr Surg 2002; 110:1598
Table 1. Adverse Event Reports to the FDA for Disposable Continuous Infusion Pumps for Direct Anesthetic Infusion into Surgical Wounds
Image not available
Table 1. Adverse Event Reports to the FDA for Disposable Continuous Infusion Pumps for Direct Anesthetic Infusion into Surgical Wounds